OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg

Flemingsberg continues to be a natural choice for knowledge-intensive and innovative businesses. OptiCell Solutions is a company that recently launched its operations at Novum Labs on Campus Flemingsberg. Founded in 2024 by specialists from Karolinska University Hospital and entrepreneurs from the Life Science industry, the company specializes in improving the availability of high-quality target cells for cell and gene therapies, a critical component of the growing ATMP (Advanced Therapy Medicinal Products) sector.

Collecting High-Quality Target Cells – A Bottleneck
“Rapid access to high-quality cells can save lives,” says Jarmo Henriksson, CEO and the visionary founder of the newly established company OptiCell Solutions. Using advanced apheresis technology*, OptiCell Solutions enables the collection of cells from voluntary study participants, cell donors, and patients without delays.

“We aim to enhance access to new treatment options for patients with chronic diseases, offering our services to biotech companies, pharmaceutical companies, medical technology firms, CROs, and healthcare providers,” explains Jarmo Henriksson.

Flemingsberg – A Strategic Choice
OptiCell Solutions has chosen Flemingsberg as the base for its operations, a hub for innovation in Life Science and a growing ATMP cluster. Located near the Karolinska ATMP Center and Karolinska University Hospital, and within the flexible laboratory hotel Novum Labs, the company benefits from proximity to leading research and healthcare institutions.

“This geographical location supports the company’s vision of simplifying cell collection and accelerating the development of cell and gene therapies.”

Patient-Centered and Efficient Approach
OptiCell Solutions’ technology, called leukapheresis, enables the gentle and efficient collection of necessary cells. This method can yield at least 20 times more target cells compared to standard blood donations, while returning the blood to the donor for increased safety.

“At OptiCell Solutions, we prioritize creating a safe and comfortable environment for cell donors. With our apheresis technology, bright facilities, and comfortable treatment chairs, we ensure high-quality cell materials while providing a positive experience for donors,” says Jarmo Henriksson.

What Are Your Future Goals?

“OptiCell Solutions’ long-term goal is to become a leading player in cell collection for cell and gene therapies. We see great potential in Flemingsberg as a future center for innovation and collaboration within Life Science,” says Jarmo.

Finally, Jarmo shares that OptiCell Solutions also envisions supporting the development of precision medicine by ensuring access to high-quality target cells across Europe, a crucial factor for the success of biological drugs and innovative treatments.

*Apheresis technology involves separating blood into its components using centrifugation during ongoing leukapheresis.